Fig. 6: Identification of a point mutation in the EHF gene.
From: EHF suppresses cancer progression by inhibiting ETS1-mediated ZEB expression
A Amino acid comparison of a part of the ETS domain is shown in ELF3 (top) and EHF (bottom). Arrowheads indicate mutation previously annotated in the TCGA dataset or previous reports. Identification of a novel L285P mutation in EHF in breast cancer cells indicated with a red arrow. H.S Homo sapiens, M.M Mus musculus, C.L Canis lupus. B, C, D, and E Expression plasmids for EHF and its derivative mutants were transfected into COS7 cells and examined by IB (B and E), immunofluorescence (C), and luciferase analysis (D). F, G, and H TSU and HOC313 cells were infected with lentiviruses carrying control (cont.), flag-tagged EHF-SF, or flag-tagged EHF-SF-L285P, and subjected to IB analysis (F), motility assays using Boyden chamber assay with inserts coated with type I collagen gel (upper panels) and wound healing assays (lower panels) (G), and chemoresistance assays (H). Each value represents the mean ± s.d. of triplicate determinations from a representative experiment. Similar results were obtained in at least three independent experiments. p values were determined by Student’s t-test. ns not significant; *p < 0.01, **p < 0.03. α-tubulin was used as a loading control (B, E, and F).
